Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide, a GLP-1 receptor agonist, has demonstrated significant effects on weight management in clinical studies, with participants achieving average weight reductions of 10-15% over 68 weeks in the STEP trials. However, individual response varies substantially—some patients achieve greater reductions while others experience more modest changes. This variability underscores the importance of understanding what factors may influence treatment outcomes before starting therapy.

Weight management is multifactorial, involving appetite signaling, glucose metabolism, gut hormone dynamics, and genetic predispositions. PlexusDx takes a precision-wellness approach by examining how individual genetic and biomarker profiles may provide context for understanding treatment response potential. A more personalized baseline assessment can support clearer expectations and informed shared decision-making with your healthcare provider.

How Semaglutide Affects Weight Through GLP-1 Signaling

Semaglutide binds to GLP-1 receptors in the brain, pancreas, and gastrointestinal tract. This activation increases feelings of fullness, slows gastric emptying, and improves insulin secretion. The combined effect typically results in reduced caloric intake and improved blood sugar stability, both supporting weight reduction over time.

Clinical trials show semaglutide's weight-loss effect is mediated through appetite suppression rather than metabolic rate increase. Participants report decreased hunger and food cravings within weeks of starting therapy. The magnitude of appetite reduction correlates with adherence and sustained weight loss, though individual sensitivity to GLP-1 signaling varies considerably.

Individual Response Variation: Why Some Patients Lose More Weight Than Others

Response to semaglutide is not uniform. In STEP 3 trial data, approximately 35% of participants achieved ≥15% weight loss, while 20% achieved <5% reduction at the same dose and duration. Factors influencing this variation include baseline metabolic health, insulin sensitivity, GLP-1 receptor expression patterns, and adherence to lifestyle modifications. Genetic variants in metabolic and appetite-regulation pathways may also contribute to response heterogeneity.

Factor Influencing Response Clinical Relevance
GLP-1 Receptor Genetic Variants May influence receptor sensitivity and signaling efficiency; variants like rs6923761 occur in ~40% of population
Baseline Insulin Resistance Patients with higher HOMA-IR scores often show greater initial weight loss; metabolic flexibility affects long-term response
FTO Gene Variants rs9939609 polymorphism associated with obesity predisposition; may correlate with baseline weight and treatment trajectory
Lifestyle Adherence Diet quality, physical activity, and sleep consistency are the strongest modifiable predictors of sustained weight loss

Biomarkers and Genetic Context: Understanding Your Baseline Profile

Before starting semaglutide, assessing metabolic biomarkers—fasting glucose, insulin, lipids, inflammatory markers, and liver/kidney function—provides a clinical baseline. These measurements help your provider evaluate safety and establish realistic goals. Genetic testing of peptide-pathway variants adds another layer of context by revealing individual predispositions in GLP-1 signaling, appetite regulation, and metabolic genes.

The Precision Peptide Genetic Test examines key variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These variants may help provide context for how your metabolic system is wired, though they do not predict exact medication response. When interpreted alongside biomarkers and clinical history, genetic insights can support a more informed conversation with your provider about whether semaglutide aligns with your metabolic profile.

Safety Considerations and Who Should Pursue This Treatment

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Common side effects include gastrointestinal effects (nausea, vomiting, constipation), particularly during dose escalation. Dehydration risk is elevated in patients with reduced oral intake; adequate fluid and nutrient intake must be maintained throughout therapy.

Compounded semaglutide formulations (administered as injections or oral tablets) are offered through licensed 503A pharmacies and provide alternatives to branded options at variable dosing and pricing. Your provider should confirm compounded vs. branded suitability based on your clinical profile, insurance, and preference. Regular monitoring of weight, metabolic markers, and side effects is essential to ensure sustained benefit and safety.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for individual variability in semaglutide response by examining genetic predispositions in GLP-1 receptor signaling, appetite-regulation pathways, and metabolic genes. Understanding your genetic baseline—alongside clinical biomarkers—can inform a more personalized conversation with your provider about whether semaglutide or alternative GLP-1 agents align with your biology.

The genetic variants tested (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) reveal predispositions in peptide metabolic pathways, not pharmacogenetic drug metabolism. These insights do not predict exact medication response; rather, they contextualize your inherent appetite regulation and metabolic wiring. This information should be interpreted with a qualified healthcare provider as one component of a comprehensive treatment-selection process.

By combining genetic predisposition data with clinical biomarkers and medical history, you and your provider can make a more informed decision about semaglutide initiation, dosing strategy, and realistic expectation-setting. PlexusDx compounded semaglutide options ($149/mo for injections; $209+/month for oral formulations) offer flexible access while your provider uses all available data to optimize your treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves